As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Lava Therapeutics N.V. The largest reported stake is Shay Capital LLC's, at 9.9%. 6 filings are on record since September 18, 2025 (Schedule 13G, September 26, 2025).
Sell to companies like Lava Therapeutics N.V? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Cooperatieve Gilde Healthcare IV U.A. · Sole voting: 0 · Shared voting: 1,014,751 · Sole dispositive: 0 · Shared dispositive: 1,014,751 · SCHEDULE 13D/A, 2025-10-22
- · Holder: Cooperatieve Gilde Healthcare IV U.A. · Percent: 11.2% · SCHEDULE 13D/A
- · Holder: Cooperatieve Gilde Healthcare IV U.A. · Percent: 19.9% · SCHEDULE 13D/A
- · Reporting person: Shay Capital LLC · Sole voting: 2,596,403 · Shared voting: 0 · Sole dispositive: 2,596,403 · Shared dispositive: 0 · SCHEDULE 13G, 2025-09-26
- · Holder: Versant Venture Capital VI, L.P. · Percent: 0% · SCHEDULE 13D/A
Lava Therapeutics N.V. has 6 Schedule 13D or 13G filings on record since 2025-09-18. 1 holder's latest filing reports 5% or more of common shares, euro 0.12 nominal value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Shay Capital LLC | 9.9% | 2,596,403 | SCHEDULE 13G, 2025-09-26 | 2025-09-19 |
| 3.9% | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 | 2025-10-20 | |
| Versant Venture Capital VI, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-09-23 | 2025-09-19 |
Holding shares or following this stake? See who's behind Lava Therapeutics N.V. and the warning signs.
Free to see. No signup.
Keep reading
More on Lava Therapeutics N.V. and the records around it.
Companies that share a holder
- Versant Venture Capital VI, L.P. also filed stake reports on 3 other companies: Tempest Therapeutics, Inc. (Apr 2026), Monte Rosa Therapeutics, Inc. (Jan 2026), LENZ Therapeutics, Inc. (Nov 2025)
- Shay Capital LLC also filed stake reports on 7 other companies: Xponential Fitness, Inc. (Jun 2026), DUOS TECHNOLOGIES GROUP, INC. (May 2026), A2Z CUST2MATE SOLUTIONS CORP. (Apr 2026)
Watch Lava Therapeutics N.V.
Get an email when Lava Therapeutics N.V. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lava Therapeutics N.V.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lava Therapeutics N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lava Therapeutics N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Shay Capital LLC | 2,596,403 | 0 | 2,596,403 | 0 | SCHEDULE 13G, 2025-09-26 |
| Shay Capital Holdings LLC | 2,596,403 | 0 | 2,596,403 | 0 | SCHEDULE 13G, 2025-09-26 |
| Cooperatieve Gilde Healthcare IV U.A. | 0 | 1,014,751 | 0 | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 |
| Gilde Healthcare IV Management B.V. | 0 | 1,014,751 | 0 | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 |
| Gilde Healthcare Holding B.V. | 0 | 1,014,751 | 0 | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 |
| Manapouri B.V. | 0 | 1,014,751 | 0 | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 |
| Martemanshurk B.V. | 0 | 1,014,751 | 0 | 1,014,751 | SCHEDULE 13D/A, 2025-10-22 |
The latest filing identifies Lava Therapeutics N.V. by CUSIP N51517105 and gives its principal executive office as Yalelaan 62, Utrecht (SCHEDULE 13D/A, 2025-10-22).
Purpose of Transaction (Item 4)
Cooperatieve Gilde Healthcare IV U.A.
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: Between October 20, 2025 and October 21, 2025, Gilde Healthcare sold an aggregate of 1,933,030 Common Shares of the Issuer in open market transactions.Item 4 of the SCHEDULE 13D/A filed 2025-10-22
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | Versant Venture Capital VI, L.P. | 9% | SCHEDULE 13D/A |
| 2025-09-23 | Versant Venture Capital VI, L.P. | 0% | SCHEDULE 13D/A |
| 2025-09-26 | Shay Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-10-14 | Cooperatieve Gilde Healthcare IV U.A. | 19.9% | SCHEDULE 13D/A |
| 2025-10-17 | Cooperatieve Gilde Healthcare IV U.A. | 11.2% | SCHEDULE 13D/A |
| 2025-10-22 | Cooperatieve Gilde Healthcare IV U.A. | 3.9% | SCHEDULE 13D/A |
Questions about who owns Lava Therapeutics N.V.
Who owns Lava Therapeutics N.V.?
On this page, one holder's latest ownership filing reports 5% or more of Lava Therapeutics N.V.: Shay Capital LLC (9.9%, Schedule 13G, filed 2025-09-26).
When did Shay Capital LLC buy into Lava Therapeutics N.V.?
The filings give report dates, not purchase dates. The earliest filing from Shay Capital LLC on this page is the Schedule 13G, filed 2025-09-26, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Lava Therapeutics N.V.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.